对于晚期ALK阳性非小细胞肺癌患者，在初始疾病进展后继续使用克唑替尼进行ALK抑制的临床获益。 - Suppr | 超能文献

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

作者信息

Leduc C, Besse B

机构信息

Department of Chest Diseases, Strasbourg University Hospital, Strasbourg.

Department of Cancer Medicine, Gustave Roussy, Villejuif, France.

出版信息

Ann Oncol. 2014 Oct;25(10):2092. doi: 10.1093/annonc/mdu257. Epub 2014 Jul 17.

DOI:10.1093/annonc/mdu257

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.对于晚期ALK阳性非小细胞肺癌患者，在初始疾病进展后继续使用克唑替尼进行ALK抑制的临床获益。

Ann Oncol. 2014 Oct;25(10):2092. doi: 10.1093/annonc/mdu257. Epub 2014 Jul 17.

2

Reply to the letter to the editor 'clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC' by Ou et al.对Ou等人致编辑的信《克唑替尼在晚期ALK阳性非小细胞肺癌患者初始疾病进展后继续进行ALK抑制的临床益处》的回复

Ann Oncol. 2014 Oct;25(10):2093. doi: 10.1093/annonc/mdu258. Epub 2014 Jul 17.

3

Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer.中国晚期ALK重排非小细胞肺癌患者初始疾病进展后继续克唑替尼治疗的临床获益

Oncotarget. 2017 Jun 20;8(25):41631-41640. doi: 10.18632/oncotarget.15892.

4

A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer.一项关于晚期ALK阳性非小细胞肺癌临床病理特征及治疗的大型单中心真实世界研究。

Cancer Med. 2017 May;6(5):953-961. doi: 10.1002/cam4.1059. Epub 2017 Apr 4.

5

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.ALK 重排与 EGFR 或 KRAS 突变相互排斥：对 1683 例非小细胞肺癌患者的分析。

Clin Cancer Res. 2013 Aug 1;19(15):4273-81. doi: 10.1158/1078-0432.CCR-13-0318. Epub 2013 May 31.

6

Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.ALK 重排非小细胞肺癌克唑替尼治疗的管理：专家共识。

Lung Cancer. 2015 Feb;87(2):89-95. doi: 10.1016/j.lungcan.2014.12.010. Epub 2014 Dec 18.

7

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.ALK 阳性 NSCLC 患者初始疾病进展后继续使用克唑替尼抑制 ALK 带来的临床获益。

Ann Oncol. 2014 Feb;25(2):415-22. doi: 10.1093/annonc/mdt572.

8

Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.针对 ALK 阳性非小细胞肺癌的精准医学：超越克唑替尼。

Med Oncol. 2018 Apr 17;35(5):72. doi: 10.1007/s12032-018-1133-4.

9

New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.间变性淋巴瘤激酶阳性非小细胞肺癌的新见解

Indian J Cancer. 2017 Jan-Mar;54(1):203-208. doi: 10.4103/ijc.IJC_72_17.

10

Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.非小细胞肺癌的靶向治疗：聚焦于ALK/ROS1酪氨酸激酶抑制剂

Expert Rev Anticancer Ther. 2018 Jan;18(1):71-80. doi: 10.1080/14737140.2018.1412260. Epub 2017 Dec 6.

引用本文的文献

1

Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases.来自真实世界的临床数据：克唑替尼在中国晚期ALK重排非小细胞肺癌及脑转移患者中的疗效

Oncotarget. 2016 Dec 20;7(51):84666-84674. doi: 10.18632/oncotarget.13179.